Hormonal agents used in lowering lipoprotein(a)

Maurizio R. Soma, Michele Meschia, Fiorenza Bruschi, Joel D. Morrisett, Rodolfo Paoletti, Remo Fumagalli, PierGiorgio Crosignani

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Lipoprotein(a) (Lp(a)) plasma concentrations in Caucasian populations are classified as a quantitative genetic trait. Although the prevailing view has been that Lp(a) levels are affected by age and gender, recent data are beginning to indicate otherwise. Lp(a) levels change throughout life especially in females after menopause. Lp(a) levels decrease in women treated with anabolic steroids such as stanozolol and danazol. The Lp(a) plasma concentration is also profoundly affected by sex hormone variations during pregnancy. In men with prostatic cancer Lp(a) levels are reduced about 50% by estrogen therapy, and increased 20% by orchidectomy. We have evaluated the changes in Lp(a) and lipid levels in postmenopausal women following estrogen/progestogen replacement therapy. The mean level of Lp(a) in treated women was about 50% lower after 6 and 12 months of replacement therapy. A significant correlation between basal Lp(a) levels and the changes at either 6 or 12 months was observed, suggesting that therapy was particularly efficacious in those women with high basal Lp(a) levels. One year after therapy cessation, Lp(a) concentrations tended to return to pre-therapy values. In addition estrogen-progestogen treatment significantly lowered total-cholesterol (12%) and LDL-cholesterol (28%), and increased HDL-cholesterol (18%). From these studies it appears that sex hormones are actively involved in the modulation of plasma Lp(a) levels and that both female and male sex hormones possess a lowering effect. The results confirm a direct effect of sex hormones on Lp(a) metabolism and suggest that estrogen-progestogen treatment of postmenopausal women can improve the lipid profile not only by lowering total- and LDL-cholesterol and raising HDL cholesterol, but also by lowering plasma Lp(a).

Original languageEnglish
Pages (from-to)345-350
Number of pages6
JournalChemistry and Physics of Lipids
Volume67-68
Issue numberC
DOIs
Publication statusPublished - 1994

Fingerprint

Lipoprotein(a)
Gonadal Steroid Hormones
Estrogens
Progestins
Plasmas
LDL Cholesterol
HDL Cholesterol
Therapeutics
Stanozolol
Testosterone Congeners
Danazol
Lipids
Estrogen Replacement Therapy
Orchiectomy
Menopause
Metabolism

Keywords

  • Gender
  • Hormone replacement therapy
  • Lp(a)
  • Sex hormones

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics

Cite this

Soma, M. R., Meschia, M., Bruschi, F., Morrisett, J. D., Paoletti, R., Fumagalli, R., & Crosignani, P. (1994). Hormonal agents used in lowering lipoprotein(a). Chemistry and Physics of Lipids, 67-68(C), 345-350. https://doi.org/10.1016/0009-3084(94)90156-2

Hormonal agents used in lowering lipoprotein(a). / Soma, Maurizio R.; Meschia, Michele; Bruschi, Fiorenza; Morrisett, Joel D.; Paoletti, Rodolfo; Fumagalli, Remo; Crosignani, PierGiorgio.

In: Chemistry and Physics of Lipids, Vol. 67-68, No. C, 1994, p. 345-350.

Research output: Contribution to journalArticle

Soma, MR, Meschia, M, Bruschi, F, Morrisett, JD, Paoletti, R, Fumagalli, R & Crosignani, P 1994, 'Hormonal agents used in lowering lipoprotein(a)', Chemistry and Physics of Lipids, vol. 67-68, no. C, pp. 345-350. https://doi.org/10.1016/0009-3084(94)90156-2
Soma MR, Meschia M, Bruschi F, Morrisett JD, Paoletti R, Fumagalli R et al. Hormonal agents used in lowering lipoprotein(a). Chemistry and Physics of Lipids. 1994;67-68(C):345-350. https://doi.org/10.1016/0009-3084(94)90156-2
Soma, Maurizio R. ; Meschia, Michele ; Bruschi, Fiorenza ; Morrisett, Joel D. ; Paoletti, Rodolfo ; Fumagalli, Remo ; Crosignani, PierGiorgio. / Hormonal agents used in lowering lipoprotein(a). In: Chemistry and Physics of Lipids. 1994 ; Vol. 67-68, No. C. pp. 345-350.
@article{d46d5e918b9e4437a2d429c49da6238d,
title = "Hormonal agents used in lowering lipoprotein(a)",
abstract = "Lipoprotein(a) (Lp(a)) plasma concentrations in Caucasian populations are classified as a quantitative genetic trait. Although the prevailing view has been that Lp(a) levels are affected by age and gender, recent data are beginning to indicate otherwise. Lp(a) levels change throughout life especially in females after menopause. Lp(a) levels decrease in women treated with anabolic steroids such as stanozolol and danazol. The Lp(a) plasma concentration is also profoundly affected by sex hormone variations during pregnancy. In men with prostatic cancer Lp(a) levels are reduced about 50{\%} by estrogen therapy, and increased 20{\%} by orchidectomy. We have evaluated the changes in Lp(a) and lipid levels in postmenopausal women following estrogen/progestogen replacement therapy. The mean level of Lp(a) in treated women was about 50{\%} lower after 6 and 12 months of replacement therapy. A significant correlation between basal Lp(a) levels and the changes at either 6 or 12 months was observed, suggesting that therapy was particularly efficacious in those women with high basal Lp(a) levels. One year after therapy cessation, Lp(a) concentrations tended to return to pre-therapy values. In addition estrogen-progestogen treatment significantly lowered total-cholesterol (12{\%}) and LDL-cholesterol (28{\%}), and increased HDL-cholesterol (18{\%}). From these studies it appears that sex hormones are actively involved in the modulation of plasma Lp(a) levels and that both female and male sex hormones possess a lowering effect. The results confirm a direct effect of sex hormones on Lp(a) metabolism and suggest that estrogen-progestogen treatment of postmenopausal women can improve the lipid profile not only by lowering total- and LDL-cholesterol and raising HDL cholesterol, but also by lowering plasma Lp(a).",
keywords = "Gender, Hormone replacement therapy, Lp(a), Sex hormones",
author = "Soma, {Maurizio R.} and Michele Meschia and Fiorenza Bruschi and Morrisett, {Joel D.} and Rodolfo Paoletti and Remo Fumagalli and PierGiorgio Crosignani",
year = "1994",
doi = "10.1016/0009-3084(94)90156-2",
language = "English",
volume = "67-68",
pages = "345--350",
journal = "Chemistry and Physics of Lipids",
issn = "0009-3084",
publisher = "Elsevier Ireland Ltd",
number = "C",

}

TY - JOUR

T1 - Hormonal agents used in lowering lipoprotein(a)

AU - Soma, Maurizio R.

AU - Meschia, Michele

AU - Bruschi, Fiorenza

AU - Morrisett, Joel D.

AU - Paoletti, Rodolfo

AU - Fumagalli, Remo

AU - Crosignani, PierGiorgio

PY - 1994

Y1 - 1994

N2 - Lipoprotein(a) (Lp(a)) plasma concentrations in Caucasian populations are classified as a quantitative genetic trait. Although the prevailing view has been that Lp(a) levels are affected by age and gender, recent data are beginning to indicate otherwise. Lp(a) levels change throughout life especially in females after menopause. Lp(a) levels decrease in women treated with anabolic steroids such as stanozolol and danazol. The Lp(a) plasma concentration is also profoundly affected by sex hormone variations during pregnancy. In men with prostatic cancer Lp(a) levels are reduced about 50% by estrogen therapy, and increased 20% by orchidectomy. We have evaluated the changes in Lp(a) and lipid levels in postmenopausal women following estrogen/progestogen replacement therapy. The mean level of Lp(a) in treated women was about 50% lower after 6 and 12 months of replacement therapy. A significant correlation between basal Lp(a) levels and the changes at either 6 or 12 months was observed, suggesting that therapy was particularly efficacious in those women with high basal Lp(a) levels. One year after therapy cessation, Lp(a) concentrations tended to return to pre-therapy values. In addition estrogen-progestogen treatment significantly lowered total-cholesterol (12%) and LDL-cholesterol (28%), and increased HDL-cholesterol (18%). From these studies it appears that sex hormones are actively involved in the modulation of plasma Lp(a) levels and that both female and male sex hormones possess a lowering effect. The results confirm a direct effect of sex hormones on Lp(a) metabolism and suggest that estrogen-progestogen treatment of postmenopausal women can improve the lipid profile not only by lowering total- and LDL-cholesterol and raising HDL cholesterol, but also by lowering plasma Lp(a).

AB - Lipoprotein(a) (Lp(a)) plasma concentrations in Caucasian populations are classified as a quantitative genetic trait. Although the prevailing view has been that Lp(a) levels are affected by age and gender, recent data are beginning to indicate otherwise. Lp(a) levels change throughout life especially in females after menopause. Lp(a) levels decrease in women treated with anabolic steroids such as stanozolol and danazol. The Lp(a) plasma concentration is also profoundly affected by sex hormone variations during pregnancy. In men with prostatic cancer Lp(a) levels are reduced about 50% by estrogen therapy, and increased 20% by orchidectomy. We have evaluated the changes in Lp(a) and lipid levels in postmenopausal women following estrogen/progestogen replacement therapy. The mean level of Lp(a) in treated women was about 50% lower after 6 and 12 months of replacement therapy. A significant correlation between basal Lp(a) levels and the changes at either 6 or 12 months was observed, suggesting that therapy was particularly efficacious in those women with high basal Lp(a) levels. One year after therapy cessation, Lp(a) concentrations tended to return to pre-therapy values. In addition estrogen-progestogen treatment significantly lowered total-cholesterol (12%) and LDL-cholesterol (28%), and increased HDL-cholesterol (18%). From these studies it appears that sex hormones are actively involved in the modulation of plasma Lp(a) levels and that both female and male sex hormones possess a lowering effect. The results confirm a direct effect of sex hormones on Lp(a) metabolism and suggest that estrogen-progestogen treatment of postmenopausal women can improve the lipid profile not only by lowering total- and LDL-cholesterol and raising HDL cholesterol, but also by lowering plasma Lp(a).

KW - Gender

KW - Hormone replacement therapy

KW - Lp(a)

KW - Sex hormones

UR - http://www.scopus.com/inward/record.url?scp=0028009961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028009961&partnerID=8YFLogxK

U2 - 10.1016/0009-3084(94)90156-2

DO - 10.1016/0009-3084(94)90156-2

M3 - Article

C2 - 8187233

AN - SCOPUS:0028009961

VL - 67-68

SP - 345

EP - 350

JO - Chemistry and Physics of Lipids

JF - Chemistry and Physics of Lipids

SN - 0009-3084

IS - C

ER -